Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2015

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Cash and cash equivalents consisted of the following (in thousands):

	September 30, 2015		December 31, 2014
Cash	$	95,488	$	151,653
Certificates of deposits		8,468		—
Money market funds		104,694		13,802
Total cash and cash equivalents	$	208,650	$	165,455

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments

The amortized cost, gross unrealized holding gains or losses, and fair value of our available-for-sale investments by major investments type are summarized in the tables below (in thousands):

	September 30, 2015
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
Corporate bonds	$	132,302	$	316	$	(179	)	$	132,439
Certificated of deposits		8,217		5		—			8,222
Equity investments		124		62		—			186
Total investments	$	140,643	$	383	$	(179	)	$	140,847

	December 31, 2014
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
Corporate bonds	$	158,692	$	254	$	(514	)	$	158,432
Equity investments		124		77		—			201
Total investments	$	158,816	$	331	$	(514	)	$	158,633

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2015		December 31, 2014
Preclinical and clinical trial accruals	$	24,388	$	25,418
Payroll and related accruals		11,480		15,608
Professional services		1,764		2,401
Other		4,142		5,558
Total accrued liabilities	$	41,774	$	48,985